<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - LEVETIRACETAM</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>LEVETIRACETAM</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Monotherapy of focal seizures with or without secondary generalisation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 250 mg once daily for 1&#8211;2 weeks, then increased to 250 mg twice daily, then increased in steps of 250 mg twice daily (max. per dose 1.5 g twice daily), adjusted according to response, dose to be increased every 2 weeks.</li>
              <li class="dose child"><strong>For children 16&#8211;17 years</strong><br/>
                Initially 250 mg once daily for 1 week, then increased to 250 mg twice daily, then increased in steps of 250 mg twice daily (max. per dose 1.5 g twice daily), adjusted according to response, dose to be increased every 2 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy of focal seizures with or without secondary generalisation</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2&#8211;4 weeks.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2&#8211;4 weeks.</li>
              <li class="dose child"><strong>For children 1&#8211;5 months</strong><br/>
                Initially 7 mg/kg once daily, then increased in steps of up to 7 mg/kg twice daily (max. per dose 21 mg/kg twice daily), dose to be increased every 2 weeks.</li>
              <li class="dose child"><strong>For children 6 months&#8211;17 years (body-weight up to 50 kg)</strong><br/>
                Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight 50 kg and above)</strong><br/>
                Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2 weeks.</li>
              <li class="dose child"><strong>For children 4&#8211;17 years (body-weight up to 50 kg)</strong><br/>
                Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight 50 kg and above)</strong><br/>
                Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy of myoclonic seizures and tonic-clonic seizures</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2&#8211;4 weeks.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight up to 50 kg)</strong><br/>
                Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years (body-weight 50 kg and above)</strong><br/>
                Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2 weeks.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>




      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Halve dose in severe hepatic impairment if eGFR less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Halve dose in severe hepatic impairment if estimated glomerular filtration rate less than 60&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Reduce dose if estimated glomerular filtration rate less than 80&#8239;mL/minute/1.73&#8239;m<sup>2</sup> (consult product literature).</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Maximum 2&#8239;g daily if eGFR 50&#8211;80&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p><p>Maximum 1.5&#8239;g daily if eGFR 30&#8211;50&#8239;mL/ minute/1.73&#8239;m<sup>2</sup>.</p><p>Maximum 1&#8239;g daily if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, aggression, anorexia, anxiety, ataxia, convulsion, cough, depression, diarrhoea, dizziness, drowsiness, dyspepsia, headache, insomnia, irritability, malaise, nasopharyngitis, nausea, rash, tremor, vertigo, vomiting,
              </p>
              <p>
                <strong>uncommon:</strong> Agitation, alopecia, amnesia, blurred vision, confusion, diplopia, eczema, impaired attention, leucopenia, myalgia, paraesthesia, pruritus, psychosis, suicidal ideation, thrombocytopenia, weight changes,
              </p>
              <p>
                <strong>rare:</strong> Agranulocytosis, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hyponatraemia, neutropenia, pancreatitis, pancytopenia, Stevens-Johnson syndrome, toxic epidermal necrolysis,
              </p>
              <p>
                <strong>notKnown:</strong> Completed suicide, pancytopenia,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>For <i>intravenous infusion</i>, dilute requisite dose with at least 100&#8239;mL Glucose 5% or Sodium Chloride 0.9%; give over 15 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>For administration of <i>oral solution</i>, requisite dose may be diluted in a glass of water.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Levetiracetam for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/levetiracetam-for-preventing-seizures">www.medicinesforchildren.org.uk/levetiracetam-for-preventing-seizures</xref>
            </p>
            </section>
      </section>






      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>
            <i>Granules</i> not licensed for use in children under 6 years, for initial treatment in children with body-weight less than 25&#8239;kg, or for the administration of doses below 250&#8239;mg.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Levetiracetam doses in BNF may differ from those in product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>If switching between oral therapy and intravenous therapy (for those temporarily unable to take oral medication), the intravenous dose should be the same as the established oral dose.</p>
            </section>
      </section>









      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of LEVETIRACETAM</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,
            oral solution,

            <div id="PHP76314"><a href="../medicinalForm/PHP76314.html" data-target="#PHP76314" data-action="load">Tablet</a></div>
            <div id="PHP76348"><a href="../medicinalForm/PHP76348.html" data-target="#PHP76348" data-action="load">Granules</a></div>
            <div id="PHP76327"><a href="../medicinalForm/PHP76327.html" data-target="#PHP76327" data-action="load">Oral solution</a></div>
            <div id="PHP76320"><a href="../medicinalForm/PHP76320.html" data-target="#PHP76320" data-action="load">Solution for infusion</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
